AML Video Channel
Explore the latest insights and summaries from experts in AML.
Recommended for You
Loading...
Trending Videos This Week
Loading...
Treatment Landscape
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 233 views
- May 29, 2024
- 1
Icahn School of Medicine at Mount Sinai
Navigating aGVHD Treatment: Integrating Recent Updates in Clinical Management
FEATURING
James Ferrara
- 52 views
- May 31, 2024
2024 ASCO® Annual Meeting Insights Hub
Understanding New Strategies to Prevent and Manage Chronic GVHD
FEATURING
Betty Hamilton
- 76 views
- June 16, 2024
- 1
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 240 views
- July 8, 2024
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
FEATURING
Talha Badar
- 733 views
- July 16, 2024
- 4
Vanderbilt University Medical Center (VUMC)
Prevention and Management of Post-SCT Relapse in Acute Leukemias
FEATURING
Andrew Jallouk
- 265 views
- July 18, 2024
- 6
Vanderbilt University Medical Center (VUMC)
Pre-Transplant Management of High-Risk AML
FEATURING
Kateryna Fedorov
- 97 views
- July 18, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 3+7 is the SOC Induction Therapy for AML
FEATURING
Ant Uzay
- 58 views
- August 15, 2024
- 1
University of Miami Sylvester Comprehensive Cancer Center
Current and Emerging Treatment Approaches for Patients With AML or MDS
FEATURING
Sangeetha Venugopal
- 136 views
- August 26, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: CML, AML, ALL
FEATURING
Mariam Nawas
- 43 views
- September 3, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 7+3 Is No Longer the Standard of Care
FEATURING
Tapan Kadia
- 722 views
- September 11, 2024
- 9
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of R/R AML: Treatment Options and Case Insights
FEATURING
Valentina Bonuomo
- 42 views
- September 11, 2024
Houston Methodist
Current Treatment Landscape in Myeloid Malignancies
FEATURING
Shilpan Shah
- 60 views
- September 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 467 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 55 views
- September 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Practical Management of AML and MDS in the Elderly
FEATURING
Turgay Ulaş
- 16 views
- October 15, 2024
Cleveland Clinic Taussig Cancer Institute
Updates in APL: Current SoC and Future Directions
FEATURING
Ben Tomlinson
- 38 views
- October 22, 2024
University of Colorado Division of Hematology
2024 Updates in AML
FEATURING
Christine McMahon
- 762 views
- April 16, 2024
- 6
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 912 views
- April 16, 2024
- 5
Indy Hematology Review
Treatment of AML: Managing the Patient When Transplant Is Not an Option
FEATURING
Harry P. Erba
- 906 views
- April 17, 2024
- 7
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 356 views
- April 22, 2024
- 3
MyCancerHaven
Updates in Frontline Treatment of Fit Patients With AML
FEATURING
Ravi Vij,
Manuel Espinoza Gutarra
- 106 views
- April 30, 2024
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
FEATURING
Aaron Goldberg
- 303 views
- May 2, 2024
- 4
Indy Hematology Review
Current & Emerging Therapies for AML and MDS
FEATURING
Rami Komrokji
- 166 views
- May 3, 2024
- 1
Yale Cancer Center
Summary of Promising Recent Studies in LR-MDS, HR-MDS, and R/R AML
FEATURING
Rory Shallis
- 91 views
- May 16, 2024
Yale Cancer Center
Yale Cancer Center Allogeneic Stem Cell Transplantation Updates
FEATURING
Lohith Bachegowda
- 70 views
- May 21, 2024
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 105 views
- May 22, 2024
Rush University Medical Center
Selection and Sequencing of Chronic GVHD Therapy
FEATURING
Satyajit Kosuri
- 266 views
- May 24, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of AML in Older Patients
FEATURING
Farhad Ravandi
- 204 views
- August 29, 2024
UChicago Medicine
Current Management of Accelerated/Blast-Phase MPNs
FEATURING
Anand Patel
- 77 views
- October 25, 2024
- 1
Weill Cornell Medicine Oncology & Hematology
Secondary AML: Best Therapy Options
FEATURING
Pinkal Desai
- 116 views
- November 21, 2024
MyCancerHaven
Hematopoetic Stem Cell Transplant: How I Decide
FEATURING
Ravi Vij,
Sanghee Hong
- 84 views
- August 30, 2024
- 2
ecancer
EHA 2024 Insights: APOLLO Trial Summary - ATRA + ATO vs. Standard ATRA + Chemo in High-Risk APL
FEATURING
Uwe Platzbecker
- 93 views
- July 24, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Treatment Options for AML in 2024
FEATURING
Alexander Perl
- 727 views
- March 3, 2024
- 4
Talha Badar
Challenges in the Management of TP53-Mutated AML: Potential Strategies to Improve Outcomes
- 454 views
- March 5, 2024
- 3
Moffitt Cancer Center
Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient
FEATURING
Onyee Chan
- 109 views
- March 5, 2024
Moffitt Cancer Center
Using Transplant in Patients With p53 Mutant MDS or AML
FEATURING
Hany Elmariah
- 330 views
- March 7, 2024
- 5
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
FEATURING
Catherine Lai
- 539 views
- March 11, 2024
- 3
Scripps Health
FLT3-Mutated AML: Advances in Frontline Treatment
FEATURING
Nicholas Short
- 248 views
- March 19, 2024
Scripps Health
Managing Intensive-Chemotherapy Ineligible Patients With AML
FEATURING
Courtney D. DiNardo
- 163 views
- March 20, 2024
- 2
UChicago Medicine
AML: Current Treatment Landscape and Key Recent Updates
FEATURING
Anand Patel
- 385 views
- March 20, 2024
- 3
UChicago Medicine
Updates in Transplantation and GVHD From Recent Meetings
FEATURING
Mariam Nawas
- 56 views
- March 25, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 385 views
- March 25, 2024
- 2
MyCancerHaven
Experts Discuss the Role of Stem Cell Transplant in AML
FEATURING
Ravi Vij,
Muzaffar Qazilbash
- 114 views
- April 11, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independent of Fitness for Intensive Therapy
FEATURING
Justin Watts
- 4 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results
FEATURING
Amir Fathi
- 3 views
- December 16, 2024
Therapeutic Agents
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- 302 views
- May 29, 2024
- 4
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 233 views
- May 29, 2024
- 1
Icahn School of Medicine at Mount Sinai
Integrating Targeted Therapies in AML
FEATURING
Hagop Kantarjian
- 423 views
- May 31, 2024
- 3
Stemline
A proven CD123 targeted therapy for BPDCN
FEATURING
Harry Erba
- 4,119 views
- September 4, 2024
- 9
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML
FEATURING
Wei-Ying Jen
- 248 views
- June 26, 2024
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors
FEATURING
Joshua Zeidner
- 69 views
- June 26, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML
FEATURING
Jorge Cortés
- 25 views
- June 28, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML
FEATURING
Gautam Borthakur
- 150 views
- July 1, 2024
- 2
Yale Cancer Center
The Role of Hypomethylating Agent Maintenance in AML
FEATURING
Rory Shallis
- 117 views
- July 1, 2024
Icahn School of Medicine at Mount Sinai
Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias
FEATURING
Omar Abdel-Wahab
- 57 views
- July 2, 2024
SOHO Brazil 2024
The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML
FEATURING
Jeffrey Lancet
- 136 views
- July 11, 2024
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
FEATURING
Jeffrey Lancet
- 474 views
- July 11, 2024
- 4
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp
FEATURING
Emanuele Angelucci
- 225 views
- July 23, 2024
- 1
Robert Zeiser
CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD
- 56 views
- August 13, 2024
- 1
University of Miami Sylvester Comprehensive Cancer Center
Current and Emerging Treatment Approaches for Patients With AML or MDS
FEATURING
Sangeetha Venugopal
- 136 views
- August 26, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: CML, AML, ALL
FEATURING
Mariam Nawas
- 43 views
- September 3, 2024
Daniel Wolff
The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibrosis in cGVHD – Recently FDA Approved
- 137 views
- September 6, 2024
- 1
Houston Methodist
Current Treatment Landscape in Myeloid Malignancies
FEATURING
Shilpan Shah
- 60 views
- September 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 55 views
- September 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Targeted Therapies in AML With a Focus on FLT3 Inhibitors
FEATURING
Naval Daver
- 36 views
- October 8, 2024
Brittany Ragon
Targeting cGVHD: Mechanism of Action of Axatilimab Compared to Other Available Agents
- 24 views
- October 14, 2024
Najla El-Jurdi
CSF1R's Role in Modulating Inflammation & Fibrosis in cGVHD
- 34 views
- October 16, 2024
Yale Cancer Center
Myeloid Malignancies: Hot Topics in 2024
FEATURING
Nikolai Podoltsev
- 273 views
- October 21, 2024
Marina Konopleva
Considering Venetoclax in AML and ALL - Which Patients and Why
- 58 views
- October 23, 2024
- 2
Noah Merin
Axatilimab in cGVHD: Mechanism of Action and Comparison With Current Therapeutic Agents
- 88 views
- November 10, 2024
University of Colorado Division of Hematology
2024 Updates in AML
FEATURING
Christine McMahon
- 762 views
- April 16, 2024
- 6
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 912 views
- April 16, 2024
- 5
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 356 views
- April 22, 2024
- 3
Indy Hematology Review
Current & Emerging Therapies for AML and MDS
FEATURING
Rami Komrokji
- 166 views
- May 3, 2024
- 1
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 105 views
- May 22, 2024
Rush University Medical Center
Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6
FEATURING
Eric Bhaimia
- 343 views
- May 24, 2024
Rush University Medical Center
Selection and Sequencing of Chronic GVHD Therapy
FEATURING
Satyajit Kosuri
- 266 views
- May 24, 2024
- 1
Icahn School of Medicine at Mount Sinai
BPDCN: Current and Future Directions
FEATURING
Naveen Pemmaraju
- 500 views
- May 31, 2024
- 2
Yale Cancer Center
Targeting Apoptosis in Leukemia: Lessons and Challenges
FEATURING
Marina Konopleva
- 110 views
- March 15, 2024
Scripps Health
FLT3-Mutated AML: Advances in Frontline Treatment
FEATURING
Nicholas Short
- 248 views
- March 19, 2024
Insights from 2023 ASH Annual Meeting
FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo
FEATURING
Esther Oliva
- 152 views
- March 22, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 385 views
- March 25, 2024
- 2
Yale Cancer Center
Splicing Factor Mutations in MDS: Role in Disease Biology and Potential Therapeutic Targeting
FEATURING
Stephanie Halene
- 26 views
- May 15, 2024
Rush University Medical Center
Allo-HSCT Conditioning Regimens: Current Status and Future Directions
FEATURING
Claudio Brunstein
- 266 views
- May 24, 2024
Icahn School of Medicine at Mount Sinai
Boosting MHC:TCR Interactions in AML
FEATURING
Iannis Aifantis
- 28 views
- July 2, 2024
ecancer
Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients Undergoing MMUD HCT
FEATURING
Monzr Al Malki,
Steven Devine
- 42 views
- July 24, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax in Newly Diagnosed and R/R AML
FEATURING
Maria Amaya
- 2 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independent of Fitness for Intensive Therapy
FEATURING
Justin Watts
- 4 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results
FEATURING
Amir Fathi
- 3 views
- December 16, 2024
Diagnostics & Biomarkers
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- 302 views
- May 29, 2024
- 4
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 233 views
- May 29, 2024
- 1
Icahn School of Medicine at Mount Sinai
Navigating aGVHD Treatment: Integrating Recent Updates in Clinical Management
FEATURING
James Ferrara
- 52 views
- May 31, 2024
Vanderbilt University Medical Center (VUMC)
Prevention and Management of Post-SCT Relapse in Acute Leukemias
FEATURING
Andrew Jallouk
- 265 views
- July 18, 2024
- 6
Giuseppe Francesco Milone
Steroid-Refractory GvHD Management: When to Switch From Steroids
- 76 views
- August 1, 2024
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
AML: Diagnosis, Trends, and Approaches
FEATURING
Mary-Beth Percival
- 82 views
- August 14, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Practical Approach to MRD Monitoring in AML: Assessing Treatment Efficacy and Relapse Risk
FEATURING
Tapan Kadia
- 108 views
- September 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 55 views
- September 30, 2024
Rush University Medical Center
[duplicate] Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- May 29, 2024
SOHO Brazil 2024
Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde
FEATURING
Jeffrey Lancet
- 543 views
- July 11, 2024
- 2
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 385 views
- March 25, 2024
- 2
Oncology Data Advisor
Navigating Hereditary Hematologic Malignancy Genetics
FEATURING
Sarah Bannon,
Hiam Abdel-Salam
- 26 views
- November 27, 2024
Disease Overview
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
AML: Diagnosis, Trends, and Approaches
FEATURING
Mary-Beth Percival
- 82 views
- August 14, 2024
Jesse Hirner
BPDCN: A Dermatologist's Perspective on Differential Diagnosis
- 1,666 views
- August 16, 2024
- 10
MyCancerHaven
Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPDCN
FEATURING
Ravi Vij,
Guru Murthy
- 628 views
- August 30, 2024
- 3
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 25 views
- October 7, 2024
Masonic Cancer Center, University of Minnesota
The Genetic Epidemiology and Early-Life Origins of Childhood Leukemia
FEATURING
Adam de Smith
- 10 views
- October 8, 2024
16th International Congress on Myeloproliferative Neoplasms
PV and Its Relationship to Acute Leukemia
FEATURING
Jerry L. Spivak
- 81 views
- November 26, 2024
- 2
Case Studies
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of R/R AML: Treatment Options and Case Insights
FEATURING
Valentina Bonuomo
- 42 views
- September 11, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of ATRA-Related Pneumatosis Cystoides Intestinalis in a Patient with APL
FEATURING
Emel Isleyen Kaya
- 5 views
- September 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
AML Case Discussion: FLT3-ITD+ High-Risk Disease
FEATURING
Fehmi Hindilerden
- 25 views
- September 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Case-Based Discussion of MRD in AML
FEATURING
Mehreen Ali Khan
- 19 views
- October 15, 2024
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 356 views
- April 22, 2024
- 3
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: 25 y/o With FLT3-TKD+ AML
FEATURING
Justine Anderson
- 87 views
- May 6, 2024
Tisch Cancer Institute at Mount Sinai
Tumor Board: Myeloid Sarcoma Manifesting as Small Bowel Obstruction
FEATURING
Justine Anderson
- 26 views
- May 6, 2024
- 1
Vanderbilt University Medical Center (VUMC)
Age Limits in Stem Cell Transplants and Cell Therapy
FEATURING
Reena Jayani
- 66 views
- July 22, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Practical Management of AML and MDS in the Elderly
FEATURING
Turgay Ulaş
- 16 views
- October 15, 2024
Masterclasses in Dermatology
Masterclasses from the Wards
FEATURING
Scott Elman
- 322 views
- March 6, 2024
- 2